Company
Headquarters: Seoul, South Korea
Employees: 2,155
CEO: Mr. Jong-Soo Woo Ph.D.
₩3.252 Trillion
KRW as of Jan. 1, 2025
US$2.21 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Hanmi Pharm. Co., Ltd. operates as a pharmaceutical company worldwide. It develops treatments for diabetes, obesity, cancer, autoimmune, and rare diseases. The company was founded in 1973 and is based in Seoul, South Korea.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | ₩1.569 T |
| EBITDA | ₩492.73 B |
| Gross Profit TTM | ₩829.25 B |
| Profit Margin | 11.75% |
| Operating Margin | 15.37% |
| Quarterly Revenue Growth | 10.30% |
Hanmi Pharm. Co. Ltd has the following listings and related stock indices.
Stock: KRX: 128940 wb_incandescent